BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Martin G, Beck P, Sigalet D. Gut hormones, and short bowel syndrome: The enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol 2006; 12(26): 4117-4129 [PMID: 16830359 DOI: 10.3748/wjg.v12.i26.4117]
URL: https://www.wjgnet.com/1007-9327/full/v12/i26/4117.htm
Number Citing Articles
1
D.L. Sigalet. Advances in glucagon like peptide-2 therapy. physiology, current indications and future directionsSeminars in Pediatric Surgery 2018; 27(4): 237 doi: 10.1053/j.sempedsurg.2018.07.008
2
Munir Alamo, Matías Sepúlveda, José Gellona, Mauricio Herrera, Cristián Astorga, Carlos Manterola. Sleeve Gastrectomy with Jejunal Bypass for the Treatment of Type 2 Diabetes Mellitus in Patients with Body Mass Index <35 kg/m2. A cohort studyObesity Surgery 2012; 22(7): 1097 doi: 10.1007/s11695-012-0652-x
3
Mina Rasouli, Sakineh Abbasi, Kazhal Sarsaifi, Homayoun Hani, Zalinah Ahmad, Abdul Rahman Omar. The L-Cell Isolation from Heterogonous Population of Intestinal Cell Line Using Antibiotic Selection MethodApplied Biochemistry and Biotechnology 2014; 172(1): 394 doi: 10.1007/s12010-013-0514-6
4
Ryo Sueyoshi, Matthew W. Ralls, Daniel H. Teitelbaum. Glucagon-like peptide 2 increases efficacy of distraction enterogenesisJournal of Surgical Research 2013; 184(1): 365 doi: 10.1016/j.jss.2013.03.089
5
Roger Atanga, Varsha Singh, Julie G. In. Intestinal Enteroendocrine Cells: Present and Future Druggable TargetsInternational Journal of Molecular Sciences 2023; 24(10): 8836 doi: 10.3390/ijms24108836
6
Erik Näslund, Per M. Hellström. Drug targets modulating the gut-appetite-metabolism axisDrug Discovery Today: Therapeutic Strategies 2007; 4(3): 189 doi: 10.1016/j.ddstr.2007.10.008
7
Christine S. Van Der Werf, Tara D. Wabbersen, Nai–Hua Hsiao, Joana Paredes, Heather C. Etchevers, Peter M. Kroisel, Dick Tibboel, Candice Babarit, Richard A. Schreiber, Edward J. Hoffenberg, Michel Vekemans, Sirkka L. Zeder, Isabella Ceccherini, Stanislas Lyonnet, Ana S. Ribeiro, Raquel Seruca, Gerard J. te Meerman, Sven C.D. van Ijzendoorn, Iain T. Shepherd, Joke B.G.M. Verheij, Robert M.W. Hofstra. CLMP Is Required for Intestinal Development, and Loss-of-Function Mutations Cause Congenital Short-Bowel SyndromeGastroenterology 2012; 142(3): 453 doi: 10.1053/j.gastro.2011.11.038
8
J.M. Morán Penco, M.I. Correa Antúnez, J.L. Amaya Lozano, A. Leal Macho, Jesus Salas Martinez, V. Climent. Changes in bile composition and liver ultrastructure after TPN alone and TPN with ultra-short bowel syndromee-SPEN Journal 2012; 7(2): e100 doi: 10.1016/j.eclnm.2011.12.005
9
Tatsuru Kaji, Hiroaki Tanaka, Jens J. Holst, Heather Redstone, Laurie Wallace, Elaine de Heuval, David L. Sigalet. The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the ratEuropean Journal of Pharmacology 2008; 596(1-3): 138 doi: 10.1016/j.ejphar.2008.07.070
10
Cassandra A. Cairns, Lan Xiao, Jian-Ying Wang. Posttranscriptional Regulation of Intestinal Mucosal Growth and Adaptation by Noncoding RNAs in Critical Surgical DisordersJournal of Investigative Surgery 2024; 37(1) doi: 10.1080/08941939.2024.2308809
11
David L. Sigalet, Mary E. Brindle, Dana Boctor, Bryan Dicken, Viona Lam, Lily Sia Lu, Elaine de Heuvel, Bolette Hartmann, Jens J. Holst. A safety and pharmacokinetic dosing study of glucagon-like peptide 2 in infants with intestinal failureJournal of Pediatric Surgery 2017; 52(5): 749 doi: 10.1016/j.jpedsurg.2017.01.034
12
Houssam E Mardini, Willem JS de Villiers. Teduglutide in intestinal adaptation and repair: light at the end of the tunnelExpert Opinion on Investigational Drugs 2008; 17(6): 945 doi: 10.1517/13543784.17.6.945
13
Emir Q. Haxhija, Hua Yang, Ariel U. Spencer, Hiroyuki Koga, Xiaoyi Sun, Daniel H. Teitelbaum. Modulation of mouse intestinal epithelial cell turnover in the absence of angiotensin converting enzymeAmerican Journal of Physiology-Gastrointestinal and Liver Physiology 2008; 295(1): G88 doi: 10.1152/ajpgi.00589.2007
14
Hubert Zatorski, Maciej Sałaga, Jakub Fichna. Role of glucagon-like peptides in inflammatory bowel diseases—current knowledge and future perspectivesNaunyn-Schmiedeberg's Archives of Pharmacology 2019; 392(11): 1321 doi: 10.1007/s00210-019-01698-z
15
Manabu Okawada, Jens J. Holst, Daniel H. Teitelbaum. Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndromeSurgery 2011; 150(2): 217 doi: 10.1016/j.surg.2011.05.013
16
Ulrich-Frank Pape, Sebastian Maasberg, Andreas Pascher. Pharmacological strategies to enhance adaptation in intestinal failureCurrent Opinion in Organ Transplantation 2016; 21(2): 147 doi: 10.1097/MOT.0000000000000296
17
Marli A. Robertson, David L. Sigalet, Jens J. Holst, Jon B. Meddings, Julie Wood, Keith A. Sharkey. Intestinal Permeability and Glucagon-like peptide-2 in Children with Autism: A Controlled Pilot StudyJournal of Autism and Developmental Disorders 2008; 38(6): 1066 doi: 10.1007/s10803-007-0482-1
18
Sophie Pevny, Sebastian Maasberg, Anja Rieger, Mirjam Karber, Elisabeth Blüthner, Barbora Knappe-Drzikova, Dana Thurmann, Janine Büttner, Karsten-Henrich Weylandt, Bertram Wiedenmann, Verena Alexandra Müller, Hendrik Bläker, Andreas Pascher, Ulrich-Frank Pape. Experience with teduglutide treatment for short bowel syndrome in clinical practiceClinical Nutrition 2019; 38(4): 1745 doi: 10.1016/j.clnu.2018.07.030
19
Gordon W. Moran, Joanne Pennock, John T. McLaughlin. Enteroendocrine cells in terminal ileal Crohn's diseaseJournal of Crohn's and Colitis 2012; 6(9): 871 doi: 10.1016/j.crohns.2012.01.013
20
Hans-Rudolf Berthoud, Andrew C. Shin, Huiyuan Zheng. Obesity surgery and gut–brain communicationPhysiology & Behavior 2011; 105(1): 106 doi: 10.1016/j.physbeh.2011.01.023
21
Jun Chen, Jia-Tian Dong, Xiao-Jing Li, Ye Gu, Zhi-Jian Cheng, Yuan-Kun Cai. Glucagon-like peptide-2 protects impaired intestinal mucosal barriers in obstructive jaundice ratsWorld Journal of Gastroenterology 2015; 21(2): 484-490 doi: 10.3748/wjg.v21.i2.484
22
Jacqueline J. Wessel, Samuel A. Kocoshis. Nutritional Management of Infants with Short Bowel SyndromeSeminars in Perinatology 2007; 31(2): 104 doi: 10.1053/j.semperi.2007.02.009
23
D. L. Sigalet. NONRUMINANT NUTRITION SYMPOSIUM: The role of glucagon-like peptide-2 in controlling intestinal function in human infants: Regulator or bystander?1,2,3Journal of Animal Science 2012; 90(4): 1224 doi: 10.2527/jas.2011-4704
24
David L. Sigalet, Viona Lam, Mary Brindle, Dana Boctor, Laurie Wallace, Elaine de Heuval, Bollette Hartmann, Jens J. Holst. The glucagon like peptide-2 ‘axis’: Capacity for production and response following intestinal resection or repair of gastroschisis in infantsJournal of Pediatric Surgery 2018; 53(5): 898 doi: 10.1016/j.jpedsurg.2018.02.012
25
Hector Solar, Mariana Doeyo, Mariana Ortega, Silvia De Barrio, Estela Olano, Eduardo Moreira, Martin Buncuga, Alejandra Manzur, Adriana Crivelli, Gabriel Gondolesi. Postsurgical Intestinal Rehabilitation Using Semisynthetic Glucagon‐Like Peptide‐2 Analogue (sGLP‐2) at a Referral Center: Can Patients Achieve Parenteral Nutrition and sGLP‐2 Independency?Journal of Parenteral and Enteral Nutrition 2021; 45(5): 1072 doi: 10.1002/jpen.1983
26
Harish Amin, Jens J. Holst, Bolette Hartmann, Laurie Wallace, Jim Wright, David L. Sigalet. Functional Ontogeny of the Proglucagon-Derived Peptide Axis in the Premature Human NeonatePediatrics 2008; 121(1): e180 doi: 10.1542/peds.2007-1461
27
Gordon W. Moran, Fiona C. Leslie, Scott E. Levison, John T. McLaughlin. Review: Enteroendocrine cells: Neglected players in gastrointestinal disorders?Therapeutic Advances in Gastroenterology 2008; 1(1): 51 doi: 10.1177/1756283X08093943
28
Lore Billiauws, Olivier Corcos, Francisca Joly. What's new in short bowel syndrome?Current Opinion in Clinical Nutrition & Metabolic Care 2018; 21(4): 313 doi: 10.1097/MCO.0000000000000473
29
Flavia Prodam, Simonetta Bellone, Silvia Savastio, Arianna Busti, Carla Guidi, Alice Monzani, Gianni Bona. Neonatology2012; : 281 doi: 10.1007/978-88-470-1405-3_43
30
David L. Sigalet, Mary Brindle, Dana Boctor, Linda Casey, Bryan Dicken, Sonia Butterworth, Viona Lam, Vikram Karnik, Elaine de Heuvel, Bolette Hartmann, Jens Holst. Safety and Dosing Study of Glucagon‐Like Peptide 2 in Children With Intestinal FailureJournal of Parenteral and Enteral Nutrition 2017; 41(5): 844 doi: 10.1177/0148607115609566
31
Jean‐Francois Marier, Mohamad‐Samer Mouksassi, Nathalie H. Gosselin, Martin Beliveau, Jane Cyran, John Wallens. Population Pharmacokinetics of Teduglutide Following Repeated Subcutanenous Administrations in Healthy Participants and in Patients With Short Bowel Syndrome and Crohn's DiseaseThe Journal of Clinical Pharmacology 2010; 50(1): 36 doi: 10.1177/0091270009342252
32
Tatsuru Kaji, Hiroaki Tanaka, Heather Redstone, Laurie E. Wallace, Jens J. Holst, David L. Sigalet. Temporal Changes in the Intestinal Growth Promoting Effects of Glucagon-Like Peptide 2 Following Intestinal ResectionJournal of Surgical Research 2009; 152(2): 271 doi: 10.1016/j.jss.2008.05.007
33
Michael B. Mumphrey, Zheng Hao, R. Leigh Townsend, Laurel M. Patterson, Hans-Rudolf Berthoud. Sleeve Gastrectomy Does Not Cause Hypertrophy and Reprogramming of Intestinal Glucose Metabolism in RatsObesity Surgery 2015; 25(8): 1468 doi: 10.1007/s11695-014-1547-9
34
Lore Billiauws, Julie Bataille, Vanessa Boehm, Olivier Corcos, Francisca Joly. Teduglutide for treatment of adult patients with short bowel syndromeExpert Opinion on Biological Therapy 2017; 17(5): 623 doi: 10.1080/14712598.2017.1304912
35
G.W. Moran, C. O'Neill, J.T. McLaughlin. GLP-2 enhances barrier formation and attenuates TNFα-induced changes in a Caco-2 cell model of the intestinal barrierRegulatory Peptides 2012; 178(1-3): 95 doi: 10.1016/j.regpep.2012.07.002
36
Vance L. Albaugh, Yanlin He, Heike Münzberg, Christopher D. Morrison, Sangho Yu, Hans-Rudolf Berthoud. Regulation of body weight: Lessons learned from bariatric surgeryMolecular Metabolism 2023; 68: 101517 doi: 10.1016/j.molmet.2022.101517
37
Ruben Vaidya, Joe X. Yi, T. Michael O’Shea, Elizabeth T. Jensen, Robert M. Joseph, Jeffrey Shenberger, Semsa Gogcu, Kathryn Wagner, Michael E. Msall, Amanda L. Thompson, Jean A. Frazier, Rebecca Fry, Rachana Singh. Long-Term Outcome of Necrotizing Enterocolitis and Spontaneous Intestinal PerforationPediatrics 2022; 150(5) doi: 10.1542/peds.2022-056445
38
Annika Mutanen, Mikko P. Pakarinen. Serum fasting GLP-1 and GLP-2 associate with intestinal adaptation in pediatric onset intestinal failureClinical Nutrition 2017; 36(5): 1349 doi: 10.1016/j.clnu.2016.09.002
39
David L. Sigalet, Laurie E. Wallace, Jens J. Holst, Gary R. Martin, Tatsuru Kaji, Hiroaki Tanaka, Keith A. Sharkey. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2American Journal of Physiology-Gastrointestinal and Liver Physiology 2007; 293(1): G211 doi: 10.1152/ajpgi.00530.2006
40
Kazuhiko Nakame, Tatsuru Kaji, Motoi Mukai, Shin Shinyama, Hiroshi Matsufuji. The protective and anti-inflammatory effects of glucagon-like peptide-2 in an experimental rat model of necrotizing enterocolitisPeptides 2016; 75: 1 doi: 10.1016/j.peptides.2015.07.025
41
Ryo Sueyoshi, Kathleen M. Woods Ignatoski, Manabu Okawada, Bolette Hartmann, Jens Holst, Daniel H. Teitelbaum. Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome modelAmerican Journal of Physiology-Gastrointestinal and Liver Physiology 2014; 307(4): G410 doi: 10.1152/ajpgi.00363.2013
42
Laura Gillard, Lore Billiauws, Bogdan Stan-Iuga, Lara Ribeiro-Parenti, Anne-Charlotte Jarry, Jean-Baptiste Cavin, Françoise Cluzeaud, Camille Mayeur, Muriel Thomas, Jean-Noël Freund, Jean-Marc Lacorte, Maude Le Gall, André Bado, Francisca Joly, Johanne Le Beyec. Enhanced Ghrelin Levels and Hypothalamic Orexigenic AgRP and NPY Neuropeptide Expression in Models of Jejuno-Colonic Short Bowel SyndromeScientific Reports 2016; 6(1) doi: 10.1038/srep28345
43
Meredith C. Hitch, Jennifer A. Leinicke, Derek Wakeman, Jun Guo, Chris R. Erwin, Kathryn J. Rowland, Ellen C. Merrick, Robert O. Heuckeroth, Brad W. Warner. Ret heterozygous mice have enhanced intestinal adaptation after massive small bowel resectionAmerican Journal of Physiology-Gastrointestinal and Liver Physiology 2012; 302(10): G1143 doi: 10.1152/ajpgi.00296.2011
44
Maria C Riutort, Gigliola Alberti, Juan Cristóbal Gana, Luis A Villarroel del Pino, Lorena I Cifuentes, Marcela Rivera-Cornejo. Teduglutide for the treatment of patients with short bowel syndromeCochrane Database of Systematic Reviews 2021; 2021(7) doi: 10.1002/14651858.CD014216
45
Michael E. Höllwarth. Short Bowel Syndrome in Childhood Colloquium Series on Integrated Systems Physiology: From Molecule to Function 2014; 6(2): 1 doi: 10.4199/C00104ED1V01Y201402ISP050
46
Galina Sanaksenaho, Annika Mutanen, Antti I. Koivusalo, Laura Merras‐Salmio, Mikko P. Pakarinen. Duodenal Disaccharidase Activities During and After Weaning off Parenteral Nutrition in Pediatric Intestinal FailureJournal of Pediatric Gastroenterology and Nutrition 2017; 64(5): 777 doi: 10.1097/MPG.0000000000001347
47
Kalyana C. Venneti, Chandralal M. Hewage. Conformational and molecular interaction studies of glucagon-like peptide-2 with its N-terminal extracellular receptor domainFEBS Letters 2011; 585(2): 346 doi: 10.1016/j.febslet.2010.12.011
48
M S Mouksassi, J F Marier, J Cyran, A A Vinks. Clinical Trial Simulations in Pediatric Patients Using Realistic Covariates: Application to Teduglutide, a Glucagon-Like Peptide-2 Analog in Neonates and Infants With Short-Bowel SyndromeClinical Pharmacology & Therapeutics 2009; 86(6): 667 doi: 10.1038/clpt.2009.199
49
Michelle Cronin, Marco Ventura, Gerald F. Fitzgerald, Douwe van Sinderen. Progress in genomics, metabolism and biotechnology of bifidobacteriaInternational Journal of Food Microbiology 2011; 149(1): 4 doi: 10.1016/j.ijfoodmicro.2011.01.019
50
Manabu Okawada, Haytham Mustafa Maria, Daniel H. Teitelbaum. Distraction Induced Enterogenesis: A Unique Mouse Model Using Polyethylene GlycolJournal of Surgical Research 2011; 170(1): 41 doi: 10.1016/j.jss.2011.03.041
51
G.W. Moran, C. O'Neill, P. Padfield, J.T. McLaughlin. Dipeptidyl peptidase-4 expression is reduced in Crohn's diseaseRegulatory Peptides 2012; 177(1-3): 40 doi: 10.1016/j.regpep.2012.04.006
52
Erik Näslund, Per Grybäck, Per Hellström. Bioactive Peptides2009; : 261 doi: 10.1201/9781420061161-c12
53
Flavia Prodam, Simonetta Bellone, Roberta Ricotti, Alice Monzani, Giulia Genoni, Enza Giglione, Gianni Bona. Neonatology2018; : 535 doi: 10.1007/978-3-319-29489-6_184
54
Jean‐Francois Marier, Martin Beliveau, Mohamad‐Samer Mouksassi, Paula Shaw, Jane Cyran, Jothi Kesavan, John Wallens, Hamim Zahir, David Wells, John Caminis. Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon‐Like Peptide‐2 (GLP‐2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy SubjectsThe Journal of Clinical Pharmacology 2008; 48(11): 1289 doi: 10.1177/0091270008320605
55
Flavia Prodam, Simonetta Bellone, Roberta Ricotti, Alice Monzani, Giulia Genoni, Enza Giglione, Gianni Bona. Neonatology2016; : 1 doi: 10.1007/978-3-319-18159-2_184-1
56
Jessie A. Elliott, John V. Reynolds, Carel W. le Roux, Neil G. Docherty. Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intakeExpert Review of Endocrinology & Metabolism 2016; 11(6): 475 doi: 10.1080/17446651.2016.1245140
57
Catherine P. A. Ivory, Laurie E. Wallace, Donna-Marie McCafferty, David L. Sigalet. Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2American Journal of Physiology-Gastrointestinal and Liver Physiology 2008; 295(6): G1202 doi: 10.1152/ajpgi.90494.2008